Picture Kentro Design Corporate and Web Design Berlin 650x65px
Document › Details

Inositec AG. (1/18/18). "Press Release: Inositec AG Appoints Dr Frits van Alphen as Chief Medical Officer". Zurich.

Organisations Organisation Inositec AG
  Organisation 2 Roche (Group)
Products Product small-molecule drug
  Product 2 Inositune™ platform
Persons Person van Alphen, Frits (Inositec 201801–CMO before Roche + Vifor Pharma + Novartis)
  Person 2 Ivarrson, Mattias (Inositec 201610 CEO)

Inositec, a pioneer in the development of life-saving small molecule drugs based on inositol hexaphosphate (IP6), announced today the appointment of Frits van Alphen, MD, as Chief Medical Officer.

Dr van Alphen has over 20 years of experience in clinical development and medical affairs, employed in roles of increasing responsibility. He has joined Inositec from Roche, where he headed the operational excellence team. He previously was Chief Medical Officer at Vifor Pharma, Head Medical Affairs Europe at Novartis as well as heading their Clinical Operations team in the Netherlands. Dr van Alphen has hands-on experience running Phase I to Phase IV studies across several therapeutic areas, including cardiovascular and metabolic diseases, and nephrology. As a physician, Dr van Alphen worked several years in anesthesiology and intensive care. Dr van Alphen earned his medical degree at Leiden University, the Netherlands.

“As CMO at Inositec, I have the golden opportunity to utilize my broad experience and entrepreneurial mind-set to develop new medicines. These innovative products have the potential to significantly advance patient care in vascular and other calcification disorders, all with high unmet medical need,” said Dr van Alphen.

“Dr van Alphen is a key addition to Inositec’s team as we enter IND/CTA-enabling studies with our lead program in the vascular calcification space and fine-tune our clinical strategy in view of first-in-human studies in 2019,” said CEO Dr Mattias Ivarsson.

About Inositec

Inositec is pioneering the development of life-saving small molecule drugs based on inositol phosphate, a natural facilitator of diverse cellular functions. Using its broadly applicable InosituneTM technology to adjust the chemical and physical properties of inositol phosphate analogs, Inositec is developing a novel class of drugs currently focusing on high-unmet medical needs related to calcification disorders. Inositec was founded in December 2015 based on the award-winning research of Dr Mattias Ivarsson, Prof Jean-Christophe Leroux and Prof Bastien Castagner at ETH Zurich, Switzerland. Further information can be found at


Mattias Ivarsson
CEO and Co-Founder
+41 44 271 07 55

Halsin Partners
Mike Sinclair
+44 (0)20 7318 2955

Record changed: 2018-01-25


Picture [LSUS] – The Business Web Portal 650x65px

More documents for Inositec AG

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSA] – The Business Web Portal 650x89px

» top